Prot #TAK-573-1501: A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma

Project: Research project

Project Details

StatusActive
Effective start/end date12/8/22 → 12/8/25

Funding

  • Pharmaceutical Research Associates, Inc. (Prot #TAK-573-1501)
  • Takeda Development Center Americas, Inc. (Prot #TAK-573-1501)